Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan + Cisplatin vs Etoposide + Cisplatin in ED-SCLC
NCT00143455Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2002
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of irinotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall Survival. Started Jun 2002; status: completed.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00143455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143455.